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California Assemblyman Paul Koretz (D-West Hollywood) intro-
duced a bill to raise the legal smoking age in the state from 18
to 21. The objective of this research is to estimate the public
health and economic impacts of raising the California legal
smoking age to 21. METHODS: To estimate the health and eco-
nomic impacts, we created a dynamic computer simulation
model. The model simulates the California population as they
age and change their smoking behavior over time. Secondary
data for model parameters were obtained from publicly avail-
able sources. Population health impacts were estimated in terms
of change in smoking prevalence and the change in cumulative
quality-adjusted life-years (QALYs) to the California population
over a 50-year period. Economic impacts were measured in mon-
etary terms for medical cost savings, cost of law enforcement and
cost of checking identiﬁcation. RESULTS: Smoking prevalence
among teens (age 14–17) will drop to 2.4% from current levels
of 13.3%, an 82% reduction. There will be savings of 24 billion
and 1.47 million QALYs will be gained over a period of 50 years
compared to status quo. CONCLUSIONS: This research should
prove useful to California’s policy makers as they contemplate
legislation to raise the state’s legal smoking age.
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OBJECTIVES: Creation of Russian Registry of patients in ACS.
Pharmacoeconomic assessment of costs and consequences of
non-ST segment evaluation ACS (NSTE ACS) by traditional anti-
coagulants and LMWH enoxaparin usage. METHODS: Registry
1 was produced in July 2001 by inclusion of 50 adult hospital
patients in ACS from 59 clinics of Russian cities. A total of 1394
patients were with NSTE ACS, 64% of them received unfrac-
tionated heparin (UFH) and 7.4%—LMWH. Registry 2 was
done in 2003 according the same criteria. A total of 1185
patients from 32 clinics were enrolled. 659 of them were with
NSTE ACS, 19% were treated by UFH, 60%—by enoxaparin.
Pharmacoeconomic analysis “cost—effectiveness” was succeed
as: k = C2 - C1 / E2 - E1. Ñ2 and Ñ1—average value of Cost
per hospital patient in Registry 2 and 1 accordingly (including
costs of treatment and resource utilization). Å2 and Å1—prob-
ability of successful outcomes of the disease in Registry 2 and 1
as well, k—cost per 1% of grow of effectiveness of the treat-
ment. RESULTS: There weren’t statistical discrepancy between
clinical characteristics and duration of hospitalization of patients
into the Registry 1 and 2. A share of more effective treated
patients has been increased in Registry 2 versus Registry 1. Prob-
ability of mortality decreased by 2.3%, reinfarct—by 6.8%,
refractory angina—by 6.3% (g < 0.001). Probability of success-
ful outcomes (E2 - E1) increased by 14.9%. Ñ2 = USD 160.68;
C1 = USD 100.64; E2 = 75.9%; E1 = 61%, K = USD 4.03/ %.
CONCLUSION: Probably the rise of number of successful out-
comes of NSTE ACS in Registry 2 was affected by more active
of LMWH enoxaparin usage. Every percentage of reduction of
serious adverse effects costs extra USD 4.03 but it leads to
increase in the quality of health care and decrease in expendi-
tures on ill effects after discharge from the hospital.
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OBJECTIVES: Vitamin K antagonists (VKAs) have a narrow
therapeutic window and numerous drug and food interactions
and therefore require frequent INR monitoring. This study
aimed to estimate VKA treatment related costs in patients with
chronic nonvalvular atrial ﬁbrillation (NVAF). METHODS:
Data were collected as part of the French arm of ISAM, an Inter-
national Study of Anticoagulation Management. Cost analysis
was from a societal perspective and limited to direct medical
costs. A randomly selected sample of general practitioners (GPs)
and cardiologists (40 GPs, 19 cardiologists) established a regis-
ter of all patients who had received at least 60 consecutive days
of VKA treatment for chronic NVAF in the preceding year. Study
data were obtained from the medical record and by patient 
interview. VKA treatment related costs included INR tests, 
blood sample draws, physician consultations, nurse cost and
VKA related investigations and hospitalisations. Drug costs were
not considered. RESULTS: Of 535 eligible patients, 278 (52%)
were interviewed. A total of 3349 INR tests were collected over
a cumulative follow-up time of 259 years. The mean cost for
INR tests was 69.82€/patient/year; 40.4% of blood samples were
taken at the patient’s home by a nurse, with a mean driving dis-
tance of 4.8km, representing an additional cost of 6.37€ for each
INR taken at home (average 33.25€/patient/year). VKA treat-
ment generated 697 GP and 187 cardiologist face-to-face con-
sultations, at a cost of 70.43€/patient/year. Of 79 hospitalisations
reported during the study period, 14 were judged attributable to
VKAs by an event adjudication committee. These hospitalisa-
tions added a further 153.99€/patient/year. CONCLUSIONS:
The annual cost of ambulatory VKA follow-up was 175€ per
patient. VKA related hospitalisations in this patient sample
added 153.99€, but the exclusion of patients unable to be inter-
viewed may have resulted in underestimation of costs associated
with severe adverse events (stroke, death).
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OBJECTIVES: To perform a retrospective economic evaluation
of an 8-week clinical trial, comparing the efﬁcacy of ﬁxed daily
doses of olmesartan (20mg) versus losartan (50mg), valsartan
(80mg) and irbesartan (150mg) in patients with mild to moder-
ate essential hypertension in Spain. METHODS: A cost-
effectiveness analysis (CEA) was carried out using 2004 drug
acquisition costs for ARA-II evaluated, and proportion of
patients with controlled blood pressure (BP; diastolic BP 
< 90mmHg or a reduction from baseline ≥ 10mmHg) at week
8 as the effectiveness measurement. RESULTS: In this sort-term
study a signiﬁcantly higher reduction of DBP was achieved 
with olmesartan (-11.5mmHg, n = 145) than with losartan 
